Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development

作者：Hussain, Musaddique; Xu, Chengyun; Ahmad, Mashaal; Majeed, Abdul; Lu, Meiping; Wu, Xiling; Tang, Lanfang; Wu, Ximei^*

来源：CLINICAL PHARMACOLOGY & THERAPEUTICS, WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 484-494, 2018-09.

DOI：10.1002/cpt.1034

• ACUTE LUNG INJURY
• KERATINOCYTE GROWTH-FACTOR
• RANDOMIZED CLINICAL-TRIAL
• STEM STROMAL CELLS
• GENE-THERAPY
• HOSPITAL MORTALITY
• SEVERE SEPSIS
• DOUBLE-BLIND
• ARDS
• EFFICACY

Despite 50 years of extensive research, no definite drug is currently available to treat acute respiratory distress syndrome (ARDS), and the supportive therapies remain the mainstay of treatment. To improve drug development for ARDS, researchers need to deeply analyze the omics approaches, reevaluate the suitable therapeutic targets, resolve the problems of inadequate animal modeling, develop the strategies to reduce the heterogeneity, and reconsider new therapeutic and analytical approaches for better designs of clinical trials.

• 出版日期2018-9
• 单位浙江大学